Pediatric clinical trials helps in better understanding of a disease and eventually cure it

 

Pediatric clinical trials

One of the major challenges in conducting pediatric clinical trials is the difficulty in recruiting enough children to meet statistical requirements. Most pediatric diseases are rare and do not progress in the same manner as their adult counterparts. Therefore, the recruitment process is more challenging than for adult trials. Moreover, the pharmacodynamic profile of pediatric patients is different from that of adults, which complicates the statistical analysis. However, many countries have regulated pediatric trials, but many do not, making them impractical and ineffective. Another significant challenge in conducting pediatric trials is the need to determine dosing strategies. Adult dose information may be applicable to pediatrics, but there are a number of factors that must be taken into accounts, such as immature liver and renal function. For example, intensive sampling methods require ten to twenty samples per individual, which is inefficient when pediatric patients are involved

The Global Pediatric Clinical Trials Market size is estimated to be valued at US$ 12,571.7 million in 2020 and is expected to exhibit a CAGR of 9.0% over the forecast period (2020-2027).

The goal of a pediatric clinical trial is to better understand a disease or its effects and eventually cure it. A well-designed study is the safest way to discover new therapies. After all, the FDA has approved these drugs, which means they are accessible to all doctors. The type of study required from patients varies, from simple surveys to diagnostic tests and periodic hospital visits. A study may require a physician's oversight to ensure the safety of its patients.

Although the number of participants in a pediatric clinical trial is growing, the proportion of those in the same trial is comparatively small. Infectious diseases make up the largest proportion of large and medium-scale trials, while respiratory and immune disorders make up the majority of observational studies. Most trials enroll fewer than one hundred participants. This proportion is still high but has not increased much over the last decade. Nonetheless, it is still the largest percentage of interventional trials in this field.